We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 2.25% | 11.375 | 10.75 | 12.00 | 11.375 | 11.125 | 11.125 | 90,931 | 08:24:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 2.18M | -2M | -0.0323 | -3.52 | 7.06M |
TIDMAOR
RNS Number : 1818H
AorTech International PLC
27 November 2015
AORTECH INTERNATIONAL PLC ("AorTech", "the Company" or "the Group")
Unaudited Interim Results
For the six months ended 30 September 2015
CHAIRMAN'S STATEMENT
Trading
Trading in the half year to 30 September 2015 was in line with the Board's expectations. Revenues for the period were $380,000 and administrative costs amounted to $365,000 resulting in the Company achieving a profit at the EBITDA level. However, after charging $163,000 for amortisation of intangible assets and incurring a further $45,000 of exceptional litigation costs, the reported operating loss was $193,000. Also charged to the profit and loss account is a $363,000 finance cost relating to the residual loan note interest. At the AGM in September, shareholders approved the Company's intention to approach loan note holders to convert their residual interest into ordinary shares. This charge recognises the full cost of the shares to be issued, less the provisions previously made.
Debtor Recovery
We mentioned in the year end accounts that the last $300,000 of a long standing debtor was being recovered by monthly payments. Up to the period end, all payments had been received on the due date. Since the end of September, no payments have been received and steps are being taken to ensure full recovery of the final balance of $150,000 together with our costs of recovery. No provision has been made against this debt.
We are currently owed in excess of $300,000 by one of our licensees; a provision of $100k has been made in the accounts and legal counsel has been retained to recover all sums due.
These matters are disappointing and will, as a result, impact on the timing and potentially the values of cash flows going forward.
Maguire Litigation
A great deal of time and effort is still having to be committed by the Directors in pursuing the US litigation against AorTech's former CEO and related parties. The case is in the pre-trial discovery phase in which AorTech is able to gather the evidence to support its allegations. The Directors intend to continue to vigorously pursue this action in order to protect the Company and shareholders from the actions of Maguire and other related parties.
Heart Valve
I set out a brief history and analysis of the Heart Valve project in the Annual Report and Accounts. Current commercial bioprosthetic and mechanical heart valves are compromised by either their durability or need for long term anticoagulation. Creating an analogue of the human valve out of polymer that has the benefits of current bioprosthetic and mechanical valves without the drawbacks has been recognised as the "Holy Grail" of heart valve technology for over 50 years.
There has been no real step change in surgical valve technology over the past 20 to 30 years, although evolutionary improvements have been made. There have been major developments in surgical techniques with the advent of catheter delivered valves (TAVI). By nature of the TAVI procedure, only bioprosthetic valves can be delivered this way and it is believed that the already limited durability of bioprosthetic valves may be further compromised by them being crushed into the narrow catheter. TAVI valves are currently only suitable for the much older patient who is unable to have open heart surgery.
Further independent review and initial consultation on the AorTech heart valve project has demonstrated that AorTech's Elast-Eon(TM) material is still the most appropriate polymer for making durable heart valves. The progress made in the AorTech heart valve project includes a valve design that has now completed proof of concept at clinical trials; a strong IP portfolio that comprises polymer patents; valve design and basis of manufacture; patents, significant know how and trade secrets regarding design history and manufacturing processes.
We have now identified a team of industry specialists covering the key areas of manufacturing, quality, regulatory, clinical marketing and business development expertise. The team has reviewed and bought into the potential for a polymer valve utilising AorTech's technology.
The market opportunities have been analysed for this disruptive technology as well as the surgical version of the valve being a replacement for current technology in the developed western markets. The ability to use inexpensive mass production techniques will produce a cost effective solution for developing countries where rheumatic heart disease is so prevalent and young patients require a relatively low cost valve that is both durable and avoids anticoagulation. In addition, in the area of TAVI, the valve leaflets can be incorporated into a TAVI stent and dry stored and pre-loaded in a smaller catheter, thus dramatically improving TAVI technology.
A non-binding Heads of Terms has been agreed whereby AorTech will transfer its Heart Valve technology into a new company established with the objective of replicating the testing work under regulatory conditions and which will then commercialise the valve in both surgical and TAVI uses.
The deal is contingent upon the new company raising sufficient funding in order to set up a manufacturing plant and take the heart valve through initial regulatory testing. AorTech will have a significant equity interest in the new company together with future royalty income. I will personally have a directorship in the new company and I am presently working with the team members identified to raise the necessary finance and establish a manufacturing facility. Discussions and meetings on the project have been positive to date and I would be hopeful that AorTech could make a formal announcement in due course. Should the transaction proceed, it will constitute a related party transaction under the AIM rules.
Conclusion
The business continues to make progress and our Manufacturing Licensee has a growing prospects list. We recently commissioned a detailed report from a world leading biomaterials expert to review the potential of AorTech's IP portfolio. The report is extremely positive in that the Elast-Eon(TM) family of materials continues to be the leading material for implantable medical devices. Your Board, in conjunction with the author of the report will be reviewing all of the recommendations contained therein. A range of opportunities have been identified which also includes the filing of additional patents to further strengthen AorTech's IP portfolio.
Your Board, despite the problems and issues which have arisen over the past two years, remain enthusiastic about the potential of Elast-Eon(TM), not just in the field of heart valves but also in other exciting medical device applications.
Bill Brown, Chairman
25 November 2015
CONDENSED CONSOLIDATED INTERIM INCOME STATEMENT Six months ended 30 September 2015 Unaudited Unaudited Audited Twelve months Six months Six months to 31 to 30 to 30 March Note Sept 2015 Sept 2014 2015 US$000 US$000 US$000 Revenue 380 524 844 -------------------- -------------------- ---------------- Other income - - 13 -------------------- -------------------- ---------------- Cost of sales - (46) - Administrative expenses (365) (340) (776) Exceptional administrative expenses 2 (45) (212) (204) Other expenses - amortisation of intangible assets 7 (163) (141) (332) -------------------- -------------------- ---------------- Operating loss (193) (215) (455) Finance income / (expense) 3 (363) 117 129 -------------------- -------------------- ---------------- Loss from continuing operations attributable to owners of the parent company (556) (98) (326) -------------------- -------------------- ---------------- Loss from discontinued operations 4 - - (44) -------------------- -------------------- ---------------- Loss attributable to owners of the parent company (556) (98) (370) Taxation - - - -------------------- -------------------- ---------------- Loss attributable to equity holders of
(MORE TO FOLLOW) Dow Jones Newswires
November 27, 2015 02:33 ET (07:33 GMT)
1 Year Rua Life Sciences Chart |
1 Month Rua Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions